GKOS Quote, Financials, Valuation and Earnings

Globus Medical, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 17.01%. Glaukos Corp.'s return on equity of -25.22% beat Globus Medical, Inc.'s return on equity of 12.49%.

Glaukos Corp. has a consensus price target of $138.75, signalling upside risk potential of 23.04%. On the other hand Globus Medical, Inc. has an analysts' consensus of $110.08 which suggests that it could grow by 25.21%. Given that Globus Medical, Inc. has higher upside potential than Glaukos Corp., analysts believe Globus Medical, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.780, which suggesting that the stock is 21.977% less volatile than S&P 500. In comparison Globus Medical, Inc. has a beta of 1.089, suggesting its more volatile than the S&P 500 by 8.928%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Globus Medical, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than Globus Medical, Inc. quarterly revenues of $826.4M. Glaukos Corp.'s net income of -$133.7M is lower than Globus Medical, Inc.'s net income of $140.6M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Globus Medical, Inc.'s PE ratio is 22.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.72x versus 4.11x for Globus Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 27.89%. Glaukos Corp.'s return on equity of -25.22% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Glaukos Corp. has a consensus price target of $138.75, signalling upside risk potential of 23.04%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $605.08 which suggests that it could grow by 33.85%. Given that Intuitive Surgical, Inc. has higher upside potential than Glaukos Corp., analysts believe Intuitive Surgical, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.780, which suggesting that the stock is 21.977% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.677, suggesting its more volatile than the S&P 500 by 67.7%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Glaukos Corp.'s net income of -$133.7M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 55.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.72x versus 15.86x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of -417.92%. Glaukos Corp.'s return on equity of -25.22% beat Plus Therapeutics, Inc.'s return on equity of --.

Glaukos Corp. has a consensus price target of $138.75, signalling upside risk potential of 23.04%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $146.88 which suggests that it could grow by 4025.7%. Given that Plus Therapeutics, Inc. has higher upside potential than Glaukos Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.780, which suggesting that the stock is 21.977% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 1.025, suggesting its more volatile than the S&P 500 by 2.509%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Glaukos Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Glaukos Corp. quarterly revenues are $143.1M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Glaukos Corp.'s net income of -$133.7M is lower than Plus Therapeutics, Inc.'s net income of -$5.7M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.72x versus 3.21x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ResMed, Inc. has a net margin of -93.39% compared to Glaukos Corp.'s net margin of 27.59%. Glaukos Corp.'s return on equity of -25.22% beat ResMed, Inc.'s return on equity of 25.44%.

Glaukos Corp. has a consensus price target of $138.75, signalling upside risk potential of 23.04%. On the other hand ResMed, Inc. has an analysts' consensus of $296.87 which suggests that it could grow by 32.48%. Given that ResMed, Inc. has higher upside potential than Glaukos Corp., analysts believe ResMed, Inc. is more attractive than Glaukos Corp..

Glaukos Corp. has a beta of 0.780, which suggesting that the stock is 21.977% less volatile than S&P 500. In comparison ResMed, Inc. has a beta of 0.928, suggesting its less volatile than the S&P 500 by 7.224%.

Glaukos Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed, Inc. offers a yield of 1.03% to investors and pays a quarterly dividend of $0.60 per share. Glaukos Corp. pays -- of its earnings as a dividend. ResMed, Inc. pays out 22.3% of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Glaukos Corp. quarterly revenues are $143.1M, which are smaller than ResMed, Inc. quarterly revenues of $1.4B. Glaukos Corp.'s net income of -$133.7M is lower than ResMed, Inc.'s net income of $392.6M. Notably, Glaukos Corp.'s price-to-earnings ratio is -- while ResMed, Inc.'s PE ratio is 22.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Glaukos Corp. is 12.72x versus 6.13x for ResMed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.